----item----
version: 1
id: {4D25A0C6-00A6-459C-B8C7-2281AFE028A8}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/10/04/Generics lobby group establishes biosimilars arm
parent: {573CFD6E-B2DD-45CD-ABE4-2EE91F9C3735}
name: Generics lobby group establishes biosimilars arm
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 8d2d8f14-e9a8-483a-bfad-a7b00cc9690b

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{F5161CC2-772F-472E-A21C-BF196343462E}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 49

Generics lobby group establishes biosimilars arm 
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 48

Generics lobby group establishes biosimilars arm
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 2579

<p>The Generic Pharmaceutical Association (GPhA) on 16 April launched a new division concentrated on the biosimilars industry.</p><p>GPhA said its Biosimilars Council will work to ensure a "positive regulatory, reimbursement, political and policy environment for patient access to biosimilar medicines and will educate the public and patients about the safety and effectiveness of biosimilars." </p><p>Areas of focus for GPhA's new biosimilars arm will include education, access, the nascent regulatory environment, reimbursement and legal affairs. </p><p>"In addition to being a voice with policymakers, this new division will be an invaluable partner for patients, providers, manufacturers, consumer groups and stakeholders from all corners of the supply chain seeking to stay apprised of critical developments regarding biosimilars," said GPhA chairman Craig Wheeler, president and CEO of Momenta Pharmaceuticals.</p><p>So far, only one biosimilar has been approved in the US &ndash; <a href="http://www.scripintelligence.com/home/NovartisSandoz-make-history-with-1st-US-biosimilar-Zarxio-357116" target="_new">Zarxio (filgrastim-sndz)</a>, from Novartis and its Sandoz unit.</p><p>But other firms have applications before the FDA, including Apotex's <a href="http://www.scripintelligence.com/policyregulation/Apotex-2nd-biosimilar-under-FDA-review-seeks-filgrastim-OK-356810" target="_new">version of filgrastim</a> and its biosimilar of Amgen's Neulasta (<a href="http://##http://www.scripintelligence.com/policyregulation/Apotex-biosimilar-of-Amgens-Neulasta-under-FDA-review-355732" target="_new">pegfilgrastim</a>); Hospira's <a href="http://www.scripintelligence.com/policyregulation/Hospira-seeks-FDA-nod-for-EpogenProcrit-biosimilar-356100" target="_new">epoetin alfa version</a> of Amgen's Epogen and Johnson & Johnson's Procrit; and Celltrion's <a href="http://www.scripintelligence.com/home/First-US-biosimilar-MAb-on-the-horizon-as-Celltrion-files-Remsima-353328" target="_new">infliximab biosimilar</a> of J&J's Remicade.</p><p>GPhA's Biosimilar Council also released an educational <a href="http://www.biosimilarscouncil.org/pdf/GPhA-biosimilars-handbook.pdf" target="_new">handbook</a> on 16 April, <i>The Next Frontier for Improved Access to Medicines: Biosimilars and Interchangeable Biologic Products</i>, which the group said explains the benefits and science behind biosimilar medicine, who will benefit from access to the products, the legal and regulatory framework and the quality manufacturing and development process.</p><p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 130

<p>The Generic Pharmaceutical Association (GPhA) on 16 April launched a new division concentrated on the biosimilars industry.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 48

Generics lobby group establishes biosimilars arm
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151004T170000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151004T170000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151004T170000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028457
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 49

Generics lobby group establishes biosimilars arm 
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357836
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042330Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

8d2d8f14-e9a8-483a-bfad-a7b00cc9690b
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042330Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
